Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Selling, General & Admin · Q4 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q4 FY2026 selling, general & admin of $67.16M rose 80.6% year over year, ahead of the +64.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 42.5% from the prior quarter. Over 3 fiscal years it compounded at +30.5% a year.

Context

  • Selling, general & admin amounted to 44.8% of revenue in FY2026, up 30.1 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of $1.76B (+771.6%) for the fiscal year ending Sep 2027, a step up from the +65.7% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$67.16M+42.5% QoQ
Last fiscal yearSep 2026
$202.05M+65.7% YoY
LTMSep 2026
$201.04M+64.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+80.6%+440.7%+360.1 pp
1 year+65.7%+771.6%+705.9 pp
3-year CAGR+30.5%+204.9%+174.4 pp
5-year CAGR+139.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2026
202.05M USD
Year-over-year change
+65.7%
4-year CAGR
+12.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +64.9% is the 2nd highest of 6, against a peer median of +22.1%.
  • Selling, general & admin amounts to 44.6% of revenue for ARWR, versus a peer median of 101.3%.
ARWR Competitors
Selling, General & Admin for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.32B USD+22.1%+16.3%27.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M USD+66.3%+37.9%61.0%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$201.04M USD+64.9%+30.5%44.6%
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M USD+23.9%+14.3%110.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
Peer median (excluding ARWR) —+22.1%+8.2%101.3%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.